Richard P. Baum

Robert Koch Allee 9
Bad Berka, TH 99437, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 200 publications

Shades of insulinoma one century after first extensive evaluation by Wilder and colleagues; a figurative review between light and dark.

Shades of insulinoma one century after first extensive evaluation by Wilder and colleagues; a figurative review between light and dark.

Journal: Reviews in endocrine & metabolic disorders

Published: May 26, 2026

Recurrent Metastatic Esthesioneuroblastoma: First-in-human α/β PRRT With Actinium-225/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT.

Recurrent Metastatic Esthesioneuroblastoma: First-in-human α/β PRRT With Actinium-225/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT.

Journal: Clinical nuclear medicine

Published: April 18, 2026

Antitumor efficacy and safety of locoregional [177Lu]Lu-RM26 radionuclide therapy in glioblastoma.

Antitumor efficacy and safety of locoregional [177Lu]Lu-RM26 radionuclide therapy in glioblastoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 15, 2026

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Journal: Lancet (London, England)

Published: December 04, 2025

Current status of FAP therapy in solid tumors.

Current status of FAP therapy in solid tumors.

Journal: Seminars in nuclear medicine

Published: November 20, 2025

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 13, 2025

Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.

Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: September 11, 2025

Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.

Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.

Journal: Theranostics

Published: August 07, 2025

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

Journal: Clinical nuclear medicine

Published: July 08, 2025

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Journal: Cancers

Published: June 30, 2025

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

Journal: Clinical nuclear medicine

Published: June 23, 2025

Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.

Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors.

Journal: Journal of neuroendocrinology

Published: June 13, 2025

Showing 1-12 of 200

Last Updated: 09/26/2026